Angela Volkert

685 citations

16 papers · 480 indexed · h-index 6

Hematology top 2%
- Acute Myeloid Leukemia Research 9
- Chronic Myeloid Leukemia Treatments 5
Genetics top 5%
- Chronic Lymphocytic Leukemia Research 3
Rheumatology top 10%
Oncology
- CAR-T cell therapy research 3
Pathology and Forensic Medicine
- Lymphoma Diagnosis and Treatment 4
Molecular Biology
- Protein Degradation and Inhibitors 3
- Retinoids in leukemia and cellular processes 2
Public Health, Environmental and Occupational Health
- Acute Lymphoblastic Leukemia research 2

Co-authors: Jörge E. Cortes Tim H. Brümmendorf Hagop M. Kantarjian Carlo Gambacorti‐Passerini Nadine Besson Eric Leip Anna Turkina Steven Arkin
Cited by: Hematology Genetics Rheumatology
Journals: Journal of Clinical Oncology (2 papers)Blood (10 papers)Cancer Research (1 paper)
Partner nations: United States France Japan

In The Last Decade

Angela Volkert

14 papers receiving 473 citations

Peers

Countries citing papers authored by Angela Volkert

Since Specialization

Citations

This map shows the geographic impact of Angela Volkert's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Angela Volkert with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Angela Volkert more than expected).

Fields of papers citing papers by Angela Volkert

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Angela Volkert. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Angela Volkert. The network helps show where Angela Volkert may publish in the future.

Co-authorship network

The 25 scholars most cited alongside Angela Volkert, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.

Border = papers with Angela Volkert Line = papers co-authored together Angela Volkert links everyone, so they are left out of the graph.

All Works

Sort: Min cites: Since: Top N: Style:

16 of 16 papers shown

#	Work
1	Use of tamibarotene, a potent and selective RARα agonist, in combination with azacitidine in patients with relapsed and refractory AML with RARA gene overexpression Leukemia & lymphoma ·Eytan M. Stein,Stéphane de Botton,Thomas Cluzeau,Arnaud Pigneux,Jane L. Liesveld,Rachel J. Cook,Philippe Rousselot,David A. Rizzieri,Thorsten Braun,Gail J. Roboz,Delphine Lebon,Maël Heiblig,Kristen Baker,Angela Volkert,Sofia Paul,Nisha Rajagopal,David A. Roth,Michael Kelly,Pierre Péterlin	2023	2
2	MDS-110 SELECT-MDS-1 Trial in Progress: A Phase 3 Randomized, Double-Blind, Placebo-Controlled Study of Tamibarotene/Azacitidine Versus Placebo/Azacitidine in Newly Diagnosed Adult Patients Selected for RARA-Positive Higher-Risk MDS Clinical Lymphoma Myeloma & Leukemia ·Amy E. DeZern,Pierre Fenaux,Dries Deeren,María Díez‐Campelo,Michael Lübbert,Pramila Krishnamurthy,Z.P. Nagy,Grzegorz Basak,Anna Jonáš ová,Klaus Geißler,Yishai Ofran,Angela Volkert,Kristen Baker,Jaime Chisholm,Qing Kang-Fortner,David A. Roth,Michael Kelly,Giovanni Marconi	2022	0
3	Initial Results from SELECT-AML-1, a Phase 2 Study of Tamibarotene in Combination with Venetoclax and Azacitidine in RARA-Positive Newly Diagnosed AML Patients Ineligible for Standard Induction Chemotherapy Blood ·Suman Kambhampati,Christine M. McMahon,Alireza Eghtedar,Daniel A. Pollyea,Stéphane de Botton,Arnaud Pigneux,Mohamad Cherry,Brian Ball,Gautam Borthakur,Thomas Cluzeau,Gary J. Schiller,Beibei Hu,Angela Volkert,Joanie Aasen Gausman,Graeme Hodgson,David A. Roth,Erica D. Warlick,Michael J. Kelly,Eytan M. Stein	2022	2
4	A randomized, double-blind, placebo-controlled study of tamibarotene/azacitidine versus placebo/azacitidine in newly diagnosed adult patients selected for RARA+ HR-MDS (SELECT-MDS-1). Journal of Clinical Oncology ·Amy E. DeZern,Giovanni Marconi,Dries Deeren,María Díez‐Campelo,Michael Lübbert,Pramila Krishnamurthy,Zsolt Nagy,Grzegorz Basak,Еlena V. Morozova,Klaus Geißler,Yishai Ofran,Heather H. Kelley,Angela Volkert,Kristen Baker,Qing Kang-Fortner,Catherine K. Madigan,David A. Roth,Michael Kelly,Pierre Fenaux	2022	2
5	Initial Results from a Biomarker-Directed Phase 2 Trial of SY-1425, a Potent and Selective RARα Agonist, in Combination with Azacitidine in Relapsed/Refractory Acute Myeloid Leukemia Blood ·Eytan M. Stein,Stéphane de Botton,Thomas Cluzeau,Arnaud Pigneux,Jane L. Liesveld,Rachel J. Cook,Philippe Rousselot,David A. Rizzieri,Thorsten Braun,Dale L. Bixby,Gail J. Roboz,Delphine Lebon,Maël Heiblig,Michael Kelly,Angela Volkert,Li Zhou,Qing Kang-Fortner,David A. Roth,Pierre Péterlin	2020	2
6	First-in-human phase I study of SY-5609, an oral, potent, and selective noncovalent CDK7 inhibitor, in adult patients with select advanced solid tumors. Journal of Clinical Oncology ·Kyriakos P. Papadopoulos,Manish Sharma,Erika Hamilton,Debra L. Richardson,Graeme Hodgson,Li Zhou,Angela Volkert,Hina Jolin,Catherine Madigan,Michael Kelly,David A. Roth	2020	5
7	SY-1425, a Potent and Selective RARα Agonist, in Combination with Azacitidine Demonstrates a High Complete Response Rate and a Rapid Onset of Response in RARA-Positive Newly Diagnosed Unfit Acute Myeloid Leukemia Blood ·Stéphane de Botton,Thomas Cluzeau,Carlos E. Vigil,Rachel J. Cook,Philippe Rousselot,David A. Rizzieri,Jane L. Liesveld,Pierre Fenaux,Thorsten Braun,Anne Banos,Michael R. Savona,Don Park,Michael Kelly,Angela Volkert,Li Zhou,Qing Kang-Fortner,David A. Roth,Eytan M. Stein	2020	6
8	Selection of RARA-Positive Newly Diagnosed Unfit AML Patients with Elevated RARA Gene Expression Enriches for Features Associated with Primary Resistance to Venetoclax and Clinical Response to SY-1425, a Potent and Selective RARα Agonist, Plus Azacitidine Blood ·Christopher Fiore,Michael Kelly,Angela Volkert,Li Zhou,Kate Madigan,Matthew L. Eaton,Graeme Hodgson,David A. Roth,Qing Kang-Fortner	2020	0
9	Early Results from a Biomarker-Directed Phase 2 Trial of Sy-1425 in Combination with Azacitidine or Daratumumab in Non-APL Acute Myeloid Leukemia (AML) and Myelodysplastic Syndrome (MDS) Blood ·Rachel J. Cook,Tamara K. Moyo,Jane L. Liesveld,David A. Rizzieri,Eytan M. Stein,Stéphane de Botton,Gail J. Roboz,Mikkael A. Sekeres,Joseph G. Jurcic,Azra Raza,Robert L. Redner,Dale L. Bixby,Jörge E. Cortes,K Stephens,Angela Volkert,Qing Kang,Emmanuelle di Tomaso,David A. Roth,Carlos E. Vigil	2018	4
10	A phase 2 study of inotuzumab ozogamicin in patients with indolent B‐cell non‐Hodgkin lymphoma refractory to rituximab alone, rituximab and chemotherapy, or radioimmunotherapy British Journal of Haematology ·André Goy,Andres Forero,Nina D. Wagner‐Johnston,W. Christopher Ehmann,Michaela L. Tsai,Kiyohiko Hatake,Revathi Ananthakrishnan,Angela Volkert,Erik Vandendries,Michinori Ogura	2016	40
11	Phase I Study Of Inotuzumab Ozogamicin (InO) Combined With R-GDP For Relapsed/Refractory CD22+ B-Cell Non-Hodgkin Lymphoma (B-NHL) Blood ·Randeep Sangha,Andrew Davies,Nam H. Dang,Michinori Ogura,David MacDonald,Angela Volkert,Revathi Ananthakrishnan,Kenneth T. Luu,Joseph Boni,Erik Vandendries,Yeow‐Tee Goh	2013	2
12	Weekly Inotuzumab Ozogamicin in Adult Patients with Relapsed or Refractory CD22-Positive Acute Lymphoblastic Leukemia. Blood ·Daniel J. DeAngelo,Wendy Stock,Stephen H. Petersdorf,Shaw-Ling Wang,Angela Volkert,Erik Vandendries,Anjali S. Advani	2012	6
13	Abstract 3776: Antitumor response to inotuzumab ozogamicin (INO) in patients with refractory or relapsed indolent B-cell non-Hodgkin's lymphomas (NHL): Pharmacokinetic-pharmacodynamic (PK-PD) modeling and interim results from a phase II study Cancer Research ·Kenneth T. Luu,Erik Vandendries,Angela Volkert,Michinori Ogura,André Goy,Joseph Boni	2012	2
14	Safety and efficacy of bosutinib (SKI-606) in chronic phase Philadelphia chromosome–positive chronic myeloid leukemia patients with resistance or intolerance to imatinib Blood ·Jörge E. Cortes,Hagop M. Kantarjian,Tim H. Brümmendorf,Dong‐Wook Kim,Anna Turkina,Zhi-Xiang Shen,Ricardo Pasqüini,H. Jean Khoury,Steven Arkin,Angela Volkert,Nadine Besson,Richat Abbas,Junyuan Wang,Eric Leip,Carlo Gambacorti‐Passerini	2011	348
15	Inotuzumab Ozogamicin (CMC-544) In Patients with Indolent B-Cell NHL That Is Refractory to Rituximab Alone, Rituximab and Chemotherapy, or Radioimmunotherapy: Preliminary Safety and Efficacy From a Phase 2 Trial Blood ·André Goy,Joseph W. Leach,W. Christopher Ehmann,Kiyoshi Ando,Kiyohiko Hatake,Kensei Tobinai,Tatyana Feldman,Steven Y. Hua,Angela Volkert,Erik Vandendries,Michinori Ogura	2010	17
16	A Phase 1/2 Study of SKI-606, a Dual Inhibitor of Src and Abl Kinases, in Adult Patients with Philadelphia Chromosome Positive (Ph+) Chronic Myelogenous Leukemia (CML) or Acute Lymphocytic Leukemia (ALL) Relapsed, Refractory or Intolerant of Imatinib. Blood ·Jörge E. Cortes,Hagop M. Kantarjian,Michele Baccarani,Tim H. Brümmendorf,Delong Liu,Gert J. Ossenkoppele,Angela Volkert,Becker Hewes,Laurence Moore,Charles Zacharchuk,Carlo Gambacorti	2006	42

About Angela Volkert

Angela Volkert is a scholar working on Hematology, Genetics and Pathology and Forensic Medicine, having authored 16 papers that have together received 480 indexed citations. Recurring topics across this work include Acute Myeloid Leukemia Research (9 papers), Chronic Myeloid Leukemia Treatments (5 papers), Lymphoma Diagnosis and Treatment (4 papers), Chronic Lymphocytic Leukemia Research (3 papers), CAR-T cell therapy research (3 papers), Protein Degradation and Inhibitors (3 papers), Retinoids in leukemia and cellular processes (2 papers) and Acute Lymphoblastic Leukemia research (2 papers). The work is most often cited by research in Hematology (366 citations), Genetics (313 citations) and Rheumatology (163 citations). Angela Volkert has collaborated with scholars based in United States, France and Japan. Frequent co-authors include Jörge E. Cortes, Tim H. Brümmendorf, Hagop M. Kantarjian, Carlo Gambacorti‐Passerini, Nadine Besson, Eric Leip, Anna Turkina, Steven Arkin, Richat Abbas and H. Jean Khoury. Their work appears in journals such as Journal of Clinical Oncology, Blood and Cancer Research.

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact